Le Lézard14 小时
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 ...
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic ...